Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine

Key Points

  • US health officials are reevaluating a $590 million contract for bird flu shots awarded to Moderna Inc. by the Biden administration.
  • The review is part of a broader government examination of spending on mRNA-based vaccines, following concerns over the technology's effectiveness and safety.

Summary

US health officials are currently reassessing a significant $590 million contract awarded to Moderna Inc. for the development of bird flu vaccines, a decision made in the final days of the Biden administration. This review comes amidst a broader scrutiny of expenditures on mRNA-based vaccines, the same technology that underpinned Moderna's successful Covid-19 vaccine. The contract's announcement initially boosted Moderna's stock by 13%, but recent market reactions have been less favorable, with shares dropping as much as 4% upon the news of the review. The urgency to fund such initiatives stems from a record-breaking bird flu outbreak affecting both poultry and cattle, raising concerns about potential human transmission. Critics, including Robert F. Kennedy Jr., who has recently taken a leadership role at HHS, have voiced skepticism about mRNA vaccines. This reevaluation reflects a cautious approach by the government towards vaccine development funding, especially in light of past controversies and the need for effective preparedness against future pandemics.

Riley Griffin and Ike Swetlitz
February 27, 2025
Stocks
Read article

Related news